For urologists there is a clear 🏆..? Let’s see the final cost!

Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized The latest @IBCG_BladderCA consensus in @EUplatinum offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate

✒️ Platinum Opinion Editorial in European Urology Cornu et al. (for the EAU M-LUTS Panel) call for a shift in managing male LUTS/BPO: 🔹 Stepwise “one-size-fits-all” models fall short 🔹 Evidence gaps for MiSTs & combinations 🔹 Patient factors (size, comorbidities, priorities)

⚡️ Is perioperative #durvalumab cost-effective in #MIBC? 📊 New study using German healthcare data: – +0.21 QALYs – +€13,162 cost – ICER: €61,006/QALY ✅ Cost-effective at €100K WTP (76.5% probability) #BladderCancer https://t.co/SrAAz5dnkt

🆕 @NatureCancer : MRI–pathology foundation model for #prostatecancer 🧠🧲 🔍 Used 1.3M MRI–pathology pairs to train a model 📊 MRI alone could predict tumor grade ✅ AUC >0.97, 89% grade accuracy 🚫 Moves us closer to biopsy-free diagnosis 👉Scalable, noninvasive PCa grading

You can read the abstract about the use of transperineal ultrasound in the follow-up after single incision sling surgery here! https://t.co/yqSWMPH02G vía @urotoday @UrologiaLaFe @dariocastillo7

🔝 Bladder cancer advances 2024: 1️⃣ TAR-200 intravesical delivery 2️⃣ Adjuvant ICI → doubled DFS in high-risk MIBC 3️⃣ Periop durvalumab → ↑ EFS & OS 4️⃣ ctDNA as biomarker for adjuvant ICI 5️⃣ EV+pembro → doubled OS, new 1L standard in mUC 📖 @JournalCancer DOI 👉

Enjoy https://t.co/4vuMeN49Qg

Oral at #IUCS25: Men ≥75 can achieve strong continence recovery after robotic-assisted radical #prostatectomy. At 12 months, 83% needed 0–1 pad/day, supporting surgery as a viable option beyond age alone. @OncoAlert #protatecancer #urology #cancer

🤩Glad to share my interview with @UroDocAsh on personalizing #NMIBC treatment 🙌🏼Fantastic support from @Medthority 👂Listen to it: https://t.co/RbZRQeGsg8 @IBCG_BladderCA @Uroweb @CAU_URO @AmerUrological @CANVES_ES

Great summary of TURBT complications just in time for #ibcg25 and surgical toxicity of Turbt ⬇️ 📊 72,284 TURBT, 43.5% had a complication within 30 days ➡️ Mostly minor (Clavien I–II: UTI 9%, retention 8%, irritative sx 7.6%) 💀 Major events rare (Clavien IV–V: <1%, death 1.9%)

Cisplatin saves lives, but kidneys pay a price. 🔘1 in 7 pts develop Chronic Kidney Disease After Cisplatin Treatment. Baseline eGFR is the strongest predictor, check it, discuss risks, hydrate, avoid nephrotoxins. #Nephrology #Oncology @JAMAOnc @OncoAlert @OncBrothers @Uromigos

Salvage lymph node dissection for PSMA+ #ProstateCancer Radioguidance: super cool tech Results, overall: not as impressive 2y BCR-free survival 18-30%. And 26-30% of pts had zero positive nodes. Conclusions: ▶️Avoid salvage LND ▶️Don't believe everything you see on PSMA PET

1️⃣ 📊 PSA density + mpMRI: New study finds lesion location matters! For PI-RADS 3: 🔹 PZ lesions → risk rises at PSAd ≥0.05 🔹 TZ lesions → risk rises at PSAd ≥0.13 For PI-RADS ≥4 ➡️ risk stays high regardless. 🩺 Read more: [ https://t.co/MAVA2QzTHb]

📢 New data for high-risk prostate cancer 🚀 In a STAMPEDE-like cohort staged with PSMA PET-CT, hypofractionated RT + long-term ADT (no abiraterone) achieved: ✅ 6-yr MFS: 80.7% ✅ PCSS: 95.8% ✅ OS: 94.4% Strong local control can rival systemic intensification in select cases

Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer https://t.co/lxw8AII7Tz This analysis of the SPCG-4 trial, which randomized men with early #ProstateCancer to radical prostatectomy (RP) or

New EUPlatinum Opin. in European Urology: IDC & cribriform PCa = high-risk, underdetected, poorly reproducible. Time to rethink grading, imaging, and surveillance. 📄 https://t.co/w3lBnHIFu5 #ProstateCancer #UroPath #EurUrol

New article published!! https://t.co/oxMTPBuTay The useful of transperinal ultrasound in follow-up after single incision sling surgery. Good job! @UrologiaLaFe @albertobudiaalb @dr_arlandis @EstherMtzCuenca @OriolColet @bonitras

Extended pelvic lymph node dissection during radical prostatectomy may improve metastasis-free survival in patients with intermediate- and high-risk prostate cancer, according to a multicenter study of over 2,300 cases. #TheVoiceofUrology #AUA More 👉 https://t.co/Rzjwiawp6e

Brief 🧵 1/ How common is *failure* of modern active surveillance (AS) for #ProstateCancer (PCa)? Which patients are at higher risk? Spoiler 🚨: it’s pretty simple @EurUrolOncol @UroToday @OncoAlert @PCF_Science @gu_onc @AmerUrological @Uroweb